• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ProQR Therapeutics upgraded by Citigroup with a new price target

    3/10/25 7:58:48 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRQR alert in real time by email
    Citigroup upgraded ProQR Therapeutics from Neutral to Buy and set a new price target of $4.00
    Get the next $PRQR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRQR

    DatePrice TargetRatingAnalyst
    4/29/2025$5.00Outperform
    Evercore ISI
    4/29/2025$8.00Overweight
    Cantor Fitzgerald
    3/10/2025$4.00Neutral → Buy
    Citigroup
    1/10/2025$15.00Outperform
    Oppenheimer
    10/29/2024$6.00 → $14.00Outperform → Strong Buy
    Raymond James
    11/8/2023$2.00Neutral → Buy
    Chardan Capital Markets
    3/30/2023$1.50 → $5.00Mkt Perform → Mkt Outperform
    JMP Securities
    12/22/2022$0.80 → $5.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings